After spending lots of time and efforts on clinical testing, these unique “living medicines” are finally poised to hop from the realm of clinical research to the world of mainstream medicine. To give these therapies their best chance of success, the cell and gene therapy industry needs to ensure that each step of the drug development and delivery process is as robust and cost-effective as possible.
The main challenges still lie in the manufacturing and delivery processes which needs to be closely examined for optimization opportunities to further maximize the chances for effectiveness in patients.
At the 3rd Annual Bioprocessing of Advanced Cellular Therapies Congress, scheduled from 29th - 30th May 2018, in Frankfurt, Germany, we aim to address these exact challenges from the manufacturing processes of cell and gene therapy to safety, quality, logistics and regulatory hurdles. We will also be discussing the implementation of automated, highly validated protocols and tools which can give these therapies the best chance of success.